Results 171 to 180 of about 3,679,356 (272)

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study. [PDF]

Front Pharmacol
Tian JX, Zhang P, Wang XX, Li JW, Liu DX, Liu YY, Xiao ZJ, Miao WJ.   +7 more
europepmc   +1 more source

News on hypomethylating agents: Chasing the FOX [PDF]

Cell Cycle, 2011
openaire   +1 more source

Corrigendum to "Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification" [Leukemia Research Reports 24 (2025) 100550]. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States. [PDF]

Blood Neoplasia
Mukherjee S, Dong W, Gerds AT, Carraway HE, Singh A, Advani AS, Mustafa Ali MK, Molina JC, Balderman S, Jain A, Caimi P, Anwer F, Sekeres MA, Koroukian SM.   +13 more
europepmc   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. [PDF]

Blood Neoplasia
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA.   +9 more
europepmc   +1 more source

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials [PDF]

, 2016

core   +1 more source

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study. [PDF]

Br J Haematol
Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E.   +26 more
europepmc   +1 more source

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia. [PDF]

Eur J Med Res
Shu W, Yang Q, He D, Li Y, Le J, Cai Q, Dai H, Luo L, Chen B, Gong Y, Jin D.   +10 more
europepmc   +1 more source

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis. [PDF]

Cancers (Basel)
Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T.   +13 more
europepmc   +1 more source

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal. [PDF]

Leukemia
Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Steffens Reinhardt L, Lawlor-O'Neill C, Roper EA, Humphries S, Murray HC, Mannan A, Dun MD, de Bock CE, Bowden NA, Enjeti AK, Verrills NM, Riveros C, Lê Cao KA, Lee HJ.   +18 more
europepmc   +1 more source